To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

Vivani Medical today announced that Australian authorities approved a first-in-human clinical trial for its subdermal GLP-1 ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...